The gene fusion testing market offers opportunities in developing advanced technologies like next-generation sequencing (NGS) ...

Scientists in the laboratory of Rendong Yang, Ph.D., associate professor of Urology, have developed a new large language model that can interpret transcriptomic data in cancer cell lines more ...

Gene fusions, which arise from chromosomal rearrangements, are recognised as a significant driver of oncogenesis. They result in chimeric transcripts that can encode novel protein functions, ...

Identification of specific gene fusions is critical for the successful targeted treatment of pediatric cancer patients. Researchers at Children's Hospital Los Angeles have developed a novel assay that ...

FDA orphan designation for zenocutuzumab‑zbco targets NRG1 fusion–positive advanced cholangiocarcinoma, a small molecular subset within an aggressive malignancy with <15% five-year survival. Orphan ...

Despite decades of progress in pediatric oncology, outcomes for children with high-risk or recurrent rhabdomyosarcoma (RMS) remain discouragingly low. While some patients with intermediate-risk ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, ...

CARLSBAD, Calif.--(BUSINESS WIRE)--Arima Genomics, Inc. (Arima), a company leveraging 3D genomics to reveal actionable insights that will empower researchers and clinicians to improve human health, ...

BUFFALO, N.Y., — Many childhood cancers start with a hijacking at the molecular level. A group of abnormal proteins known as fusion proteins aberrantly engage with a collection of proteins that ...

Using a novel bioinformatics approach, researchers found that the majority of prostate cancers carry a specific gene fusion, a common feature of blood cancers but relatively rare in solid tumors, ...